Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Medicine, Nuclear Medicine, Radiation Oncology +17

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Medicine, Oncology, Urology +15

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 2K citations · Full text

Medicine, Oncology, Urology +17